Solid Biosciences Crescita futura
Future criteri di controllo 0/6
Solid Biosciences's earnings are forecast to decline at 9.1% per annum while its annual revenue is expected to grow at 76% per year. EPS is expected to grow by 10% per annum.
Informazioni chiave
-9.1%
Tasso di crescita degli utili
10.0%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.1% |
| Tasso di crescita dei ricavi | 76.0% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 24 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Jul 26
Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -157 | -214 | -194 | 5 |
| 12/31/2025 | N/A | -122 | -111 | -108 | 7 |
| 12/31/2024 | N/A | -105 | -50 | -47 | 7 |
| 6/30/2024 | N/A | -91 | -86 | -85 | N/A |
| 3/31/2024 | N/A | -90 | -93 | -91 | N/A |
| 12/31/2023 | N/A | -96 | -96 | -94 | N/A |
| 9/30/2023 | N/A | -91 | -110 | -108 | N/A |
| 6/30/2023 | N/A | -90 | -113 | -110 | N/A |
| 3/31/2023 | 6 | -91 | -102 | -99 | N/A |
| 12/31/2022 | 8 | -86 | -101 | -98 | N/A |
| 9/30/2022 | 11 | -89 | -87 | -84 | N/A |
| 6/30/2022 | 15 | -87 | -85 | -82 | N/A |
| 3/31/2022 | 12 | -81 | -85 | -84 | N/A |
| 12/31/2021 | 14 | -72 | -79 | -78 | N/A |
| 9/30/2021 | 10 | -75 | -56 | -56 | N/A |
| 6/30/2021 | 7 | -78 | -53 | -53 | N/A |
| 3/31/2021 | 3 | -78 | -49 | -49 | N/A |
| 12/31/2020 | N/A | -88 | -57 | -57 | N/A |
| 9/30/2020 | N/A | -99 | -81 | -79 | N/A |
| 6/30/2020 | N/A | -107 | -85 | -83 | N/A |
| 3/31/2020 | N/A | -114 | -99 | -96 | N/A |
| 12/31/2019 | N/A | -117 | -97 | -93 | N/A |
| 9/30/2019 | N/A | -107 | -98 | -93 | N/A |
| 6/30/2019 | N/A | -97 | -96 | -89 | N/A |
| 3/31/2019 | N/A | -89 | -88 | -79 | N/A |
| 12/31/2018 | N/A | -75 | -78 | -70 | N/A |
| 9/30/2018 | N/A | -67 | -69 | -63 | N/A |
| 6/30/2018 | N/A | -62 | -63 | -57 | N/A |
| 3/31/2018 | N/A | -55 | N/A | -50 | N/A |
| 12/31/2017 | N/A | -39 | N/A | -43 | N/A |
| 9/30/2017 | N/A | -29 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -17 | N/A | -20 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: SLDB is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: SLDB is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: SLDB is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: SLDB is forecast to have no revenue next year.
Ricavi ad alta crescita: SLDB is forecast to have no revenue next year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if SLDB's Return on Equity is forecast to be high in 3 years time